Incannex Healthcare details 2025 progress, 2026 outlook

Accepted by SEC EDGAR 01/14/2026 - 07:30 AM EST

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Incannex Healthcare Inc. filed a current report to disclose that, on January 14, 2026, it issued a press release titled “Incannex Healthcare Inc. Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026.” The press release is attached as an exhibit and incorporated by reference, and is described as outlining the company’s 2025 progress and its well-funded outlook for 2026.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Incannex Healthcare Inc. (IXHL) report in its latest 8-K filing?

Incannex Healthcare Inc. filed a current report to disclose that it issued a press release on January 14, 2026 titled “Incannex Healthcare Inc. Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026.”

What is the main focus of the Incannex Healthcare (IXHL) press release referenced in the 8-K?

The press release is described as highlighting Incannex Healthcare Inc.’s transformational 2025 progress and outlining a well-funded outlook for 2026.

Which exhibit is included with the Incannex Healthcare Inc. (IXHL) 8-K filing?

The filing includes Exhibit 99.1, which is the press release of Incannex Healthcare Inc. dated January 14, 2026, and Exhibit 104, the cover page interactive data file.

Under which item did Incannex Healthcare Inc. (IXHL) disclose the press release?

Incannex Healthcare Inc. disclosed the press release under Item 8.01, labeled as Other Events.

On what date was the Incannex Healthcare Inc. (IXHL) press release issued?

The press release referenced in the filing was issued on January 14, 2026.

Who signed the Incannex Healthcare Inc. (IXHL) 8-K filing?

The filing was signed on behalf of Incannex Healthcare Inc. by Joel Latham, Chief Executive Officer and President.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2026

Incannex Healthcare Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41106

93-2403210

(State or other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

Suite 105, 8 Century Circuit Norwest,

NSW 2153 Australia

Not applicable

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, including Area Code: +61 409 840 786

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, $0.0001 par value per share		IXHL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 14, 2026, Incannex Healthcare Inc. Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Incannex Healthcare Inc., dated January 14, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Incannex Healthcare Inc.

Date: January 14, 2026		/s/ Joel Latham
	Name:	Joel Latham
	Title:	Chief Executive Officer and President

Source: View Original Filing on SEC EDGAR